MRI-based risk calculators improve discrimination for clinically significant and all prostate cancer compared to traditional models

Photo by Vitaly Gariev / Unsplash

Prostate cancer and prostatic diseases Published June 1, 2026 Medically reviewed June 1, 2026 Study authors: Courtney O'Toole Ciarán, Boakye Nancy Fosua, Hannigan Ailish, Jalali Amirhossein PubMed ↗ DOI ↗ By Dr. Lars van Dijk, PhD · Surgical, Procedural & Diagnostic

Key Takeaway

Consider MRI-based calculators for improved discrimination in prostate cancer diagnosis.

This systematic review and meta-analysis compared MRI-based risk calculators against traditional clinical risk calculators for prostate cancer diagnosis. The analysis screened 2049 papers and included 16 studies that met inclusion criteria. The primary outcome measured the Area Under the Curve for discriminatory ability.

The pooled results indicated an AUC of 0.84 for clinically significant prostate cancer and 0.81 for all prostate cancer using MRI-based tools. Traditional clinical models showed baseline AUCs of 0.76 for clinically significant disease and 0.74 for all disease. The pooled logit(AUC) difference was 0.49 units for clinically significant cancer and 0.37 units for all cancer.

The authors noted high heterogeneity likely due to prostate cancer variability. Additionally, 31% of studies had high or unclear risk of bias, which may affect generalisability. Funding or conflicts of interest were not reported. The review did not report adverse events or discontinuations.

Practice relevance suggests MRI-based risk calculators improve diagnostic accuracy with potential to reduce unnecessary biopsies. This supports integration into clinical practice while acknowledging limitations regarding study bias and heterogeneity.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedJun 2026

PMID40858922

View Original Abstract ↓

BACKGROUND: Prostate cancer (PCa) is the second most common cancer among men worldwide. Current diagnostic methods often lack sufficient sensitivity and specificity, leading to unnecessary biopsy. With growing use of MRI and EAU guideline recommendations, this review synthesised evidence on MRI-based risk calculators (RCs) for PCa diagnosis and compared their performance with traditional clinical RCs. METHODS: A systematic search of Embase, Medline, Scopus, Cochrane Library, and Web of Science databases assessed the discriminatory ability of MRI-based RCs using Area Under the Curve (AUC). A meta-analysis was conducted to pool AUC estimates, assess heterogeneity, and compare the differences in discriminatory ability. RESULTS: Of 2049 papers, 16 met the inclusion criteria. MRI-based RCs showed increased discrimination, with an AUC of 0.84 (95% CI: 0.81-0.86) for clinically significant PCa (csPCa), compared to 0.76 (95% CI: 0.73-0.79) for clinical models, and an AUC of 0.81 (95% CI: 0.78-0.84) for all PCa, compared to 0.74 (95% CI: 0.68-0.79). The pooled logit(AUC) difference was 0.49 units for csPCa and 0.37 units for all PCa. High heterogeneity was noted, likely due to PCa variability, and 31% of the studies had a high or unclear risk of bias, potentially affecting generalisability. CONCLUSIONS: MRI-based RCs improve the diagnostic accuracy for PCa with the potential to reduce unnecessary biopsies and optimise healthcare resources, thereby supporting their integration into clinical practice.